Low-Dose Anti-Thymocyte Globulin Preserves C-Peptide, Reduces HbA1c, and Increases Regulatory to Conventional T-Cell Ratios in New-Onset Type 1 Diabetes: Two-Year Clinical Trial Data

Michael J. Haller(University of Florida), Louis H. Philipson(University of Chicago), Jerry P. Palmer(University of Washington), Åke Lernmark(Lund University), Antoinette Moran(University of Minnesota), Jane H. Buckner(Benaroya Research Institute), Kevan C. Herold(Yale University), J. Lori Blanchfield(Benaroya Research Institute), Mark A. Clements(Children's Mercy Hospital), Megan Warnock(University of South Florida), Jennifer B. Marks(University of Miami), Andrew J. Muir(Duke University), Wayne D. Moore, Desmond Schatz(University of Florida), Linda A. DiMeglio(Urology of Indiana), Peter G. Colman(The Royal Melbourne Hospital), Emanuele Bosi(University of Miami), S. Alice Long(Benaroya Research Institute), Mark A. Atkinson(University of Florida), David A. Baidal(University of Miami), Carmella Evans‐Molina(Richard L. Roudebush VA Medical Center), Mark Peakman(Sanofi (France)), Brian N. Bundy(Memorial Sloan Kettering Cancer Center), Darrell M. Wilson(Stanford Medicine), Robin Goland(Columbia University), Peter A. Gottlieb(University of Colorado Health), Jeffrey P. Krischer(University of South Florida), Manuela Battaglia(Vita-Salute San Raffaele University), Stephen E. Gitelman(University of California, San Francisco), Jessica Miller(Advocate Lutheran General Hospital), Susan Geyer(University of South Florida), Dorothy J. Becker(University of Pittsburgh), P. J. Bingley(Benaroya Research Institute), Mikael Knip(Åbo Akademi University), Henry Rodriguez(University of South Florida), William E. Russell(Vanderbilt University)
Diabetes
April 9, 2019
Cited by 132


Related Papers